RHOBTB3

Across TCGA pan-cancer cohorts, RHOBTB3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RHOBTB3 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher RHOBTB3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RHOBTB3 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

GBM, PDAC, and LUAD are the cancer types where RHOBTB3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.230	0.502	.001	16	view →
PDAC	DFS	Quartile	III,IV	0.255	0.962	.038	12	view →
LUAD	DFS	Median	III,IV	0.469	0.759	.043	6	view →
LSCC	OS	Median	III,IV	1.000	0.805	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RHOBTB3–GBM (DFS)

Open the GBM breakdown →